What's in Dong Wha Pharmaceutical Co. Ltd.'s pipeline?

Dong Wha Pharmaceutical Co. Ltd. has 9 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 8 in Phase 1.

Which companies overlap with Dong Wha Pharmaceutical Co. Ltd.'s portfolio?

Top competitors by shared drug class: Hutchison Medipharma Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dong-wha-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Dong Wha Pharmaceutical Co. Ltd. — Portfolio Competitive Intelligence Brief

Dong Wha Pharmaceutical Co. Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DW6012(Dasidiem tab. 10/100mg)	DW6012(Dasidiem tab. 10/100mg)	marketed	Tyrosine kinase inhibitor combination	BCR-ABL, SRC family kinases	Oncology

Therapeutic area mix

Gastroenterology · 1
Neuroscience · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hutchison Medipharma Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dong Wha Pharmaceutical Co. Ltd.:

Cite this brief

Drug Landscape (2026). Dong Wha Pharmaceutical Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dong-wha-pharmaceutical-co-ltd. Accessed 2026-05-16.